Table 5 Demographic characteristics of Bu–Zhong–Yi–Qi–Tang use among patients with Alzheimer’s disease
From: Patterns of Chinese medicine use in prescriptions for treating Alzheimer’s disease in Taiwan
Characteristics | Bu–Zhong–Yi–Qi–Tang users (%) | CMa users not using Bu–Zhong–Yi–Qi–Tang (%) | aORb (95 % CIc) |
|---|---|---|---|
No. of cases | 685 (77.1) | 204 (22.9) | |
Age at diagnosis | |||
<45 | 5 (0.7) | 2 (1) | 0.69 (0.12–6.03) |
45–54 | 21 (3.1) | 2 (1) | 3.17 (0.70–17.44) |
55–64 | 88 (12.8) | 22 (10.8) | 1 |
65–74 | 221 (32.1) | 70 (34.3) | 0.72 (0.23–1.34) |
75–84 | 304 (44.1) | 92 (45.1) | 0.92 (0.41–1.52) |
≥85 | 45 (6.5) | 16 (7.8) | 0.64 (0.22–1.59) |
Sex | |||
Female | 377 (55.0) | 99 (48.5) | 1.23 (1.04–1.57) |
Male | 308 (45.0) | 104 (51.0) | 1 |
Numbers of anti–Alzheimer’s or BPSD drugs | |||
1 | 26 (3.8) | 11 (5.4) | 1 |
2 | 133 (19.4) | 55 (27.0) | 0.82 (0.21–2.01) |
3 | 259 (37.8) | 75 (36.8) | 1.32 (0.52–2.81) |
≥4 | 367 (39.0) | 63 (40.9) | 1.04 (0.57–2.11) |
Numbers of dementia BPSDd | |||
0 | 84 (12.3) | 42 (20.6) | 1 |
1 | 115 (16.8) | 63 (30.9) | 0.72 (0.31–1.68) |
2 | 206 (30.1) | 52 (25.5) | 2.11 (0.93–3.38) |
≥3 | 280 (40.9) | 63 (30.9) | 2.75 (0.82–4.31) |
Numbers of comorbidity | |||
0 | 22 (3.2) | 12 (5.9) | 1 |
1 | 90 (13.1) | 35 (17.2) | 1.21 (0.38–3.71) |
2 | 119 (17.4) | 57 (27.9) | 1.02 (0.31–4.23) |
≥3 | 454 (66.3) | 99 (48.5) | 2.24 (0.71–4.55) |